Last reviewed · How we verify
NCT05642988
Application of Wearable Technology in High-risk Surgical Patients in the Perioperative Period
trial testing LifeSignals 1AX Biosensor in Adult ALL in 20 participants. Completed in 1 December 2023.
1 December 2023
Quick facts
| Lead sponsor | Mater Misericordiae University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 1 March 2023 |
| Primary completion | 1 December 2023 |
| Estimated completion | 1 December 2023 |
| Sites | 1 location across Ireland |
Drugs / interventions tested
- LifeSignals 1AX Biosensor
Conditions studied
- Adult ALL — all drugs for Adult ALL →
- Surgery — all drugs for Surgery →
- Anesthesia — all drugs for Anesthesia →
- Postoperative Complications — all drugs for Postoperative Complications →
Sponsor
Mater Misericordiae University Hospital
Who can join
18 and older, any sex, with Adult ALL or Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Unrecognised changes in patients' vital signs after surgery can result in preventable complications. Current standard practice includes routine monitoring of patient vital signs up until hospital discharge. Upon discharge from hospital, all forms of routine vital sign monitoring ceases. The availability and use of wearable technology in healthcare is increasing rapidly. The role of wearable technology in the remote monitoring of patients at high-risk of post-operative complications and hospital readmission after discharge from hospital is unclear. This pilot study is aimed to assess the feasibility of using wearable technology in patients recovering from major intracavity surgery after hospital discharge in the Irish healthcare setting.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05642988
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Adult ALL
Currently open trials in the same condition.
- NCT06386861 — Validating the Spanish "Attitudes Toward Genomics and Precision Medicine" (AGPM). · NA · active not recruiting
- NCT06220487 — A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With New · Phase 2 · recruiting
Other Mater Misericordiae University Hospital trials
Trials by the same sponsor.
- NCT05181371 — ESP Block in VATS: Programmed Intermittent Bolus Versus Continuous Infusion on Quality of Recovery · NA · completed
- NCT04924010 — Effect of Perioperative CBT on Chronic Persistent Postsurgical Pain Among Breast Cancer Patients · NA · completed
- NCT04729712 — Efficacy of Ultrasound Guided ESP Vs Video-assisted PVB Catheter Placement in Minimally Invasive Thoracic Surgery · NA · completed
- NCT04370951 — Efficacy of the Erector Spinae Plane Block in Posterior Thoraco- Lumbar Spinal Decompression Surgery · NA · unknown
- NCT04220242 — Future of Colorectal Cancer Surgery · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05642988 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mater Misericordiae University Hospital
- Last refreshed: 22 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05642988.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing